ivonescimab
AssetAlso AK-112, SMT-112
Bispecific antibody blocks PD-1 and VEGF to enhance antitumor immunity and inhibit angiogenesis.
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Inflammation
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Breast cancer
Phase 3, businesswire.com, 2 Oct 2026
Lung cancer
Phase 3, businesswire.com, 2 Oct 2026
Triple-negative breast cancer
Phase 3, businesswire.com, 2 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.